Angelika Dienel
Research Subjects
Research Interests
Angelika Dienel has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Sandra Schläfke
Willmar Schwabe GmbH & Co. KG
2 shared publications- Siegfried Kasper
Medizinische Universität Wien
2 shared publications - Armin Szegedi
Global Clinical Development, Organon International, 56 Livingston Avenue, Roseland, New Jersey 07068, USA
1 shared publication Christine Klipping
Dinox B. V
1 shared publication- Doris Heger-Mahn
Dinox GmbH, Anklamerstrasse 38, 10115, Berlin, Germany
1 shared publication Günther Pabst
Formerly Focus CDD GmbH
1 shared publication
Latest Publications
- Open Access
- 16 October 2014
- Published by Springer Nature in Drugs in R&D
- Vol. 14 (4) , 265-272
No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
Silexan is an oral Lavender oil preparation with proven anxiolytic efficacy. Given the high prevalence of anxiety and restlessness in younger women, oral contraceptives and Silexan will likely be co-administered.
- 16 October 2014
- Published by Springer Nature in Drugs in R&D
- Vol. 14 (4) , 265-272
Open AccessNo Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
Silexan is an oral Lavender oil preparation with proven anxiolytic efficacy. Given the high prevalence of anxiety and restlessness in younger women, oral contraceptives and Silexan will likely be co-administered.
- 1 April 2011
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 32 (02) , 60-63
Wirksamkeit und Verträglichkeit von Silexan, einer neuen, oral verabreichten Zubereitung aus Lavendelöl, bei subsyndromaler Angststörung
Die subsyndromale Angststörung beeinflusst die Lebensqualität und die Arbeitsfähigkeit der Betroffenen und geht, ähnlich der generalisierten Angststörung (GAS), mit einem hohen Risiko der Komorbidität und mit einer geringen Spontanheilungsrate einher. Bisher gibt es keine Behandlungsrichtlinien und tatsächlich erfahren viele dieser Patienten keine Behandlung. Die frühzeitige Therapie der subsyndromalen Angst ist aber empfehlenswert, um einen Übergang in die GAS zu verhindern. Hierzu könnte Silexan, ein neues pflanzliches Arzneimittel aus Lavendelöl, beitragen. Dieser Artikel gibt einen Überblick über die klinischen Studien zur Wirksamkeit und Verträglichkeit dieses Phytopharmakons, welches zur Behandlung von Unruhezuständen bei ängstlicher Verstimmung zugelassen ist. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials On the same lines as the generalised anxiety disorder (GAD), a subthreshold also called subsyndromal anxiety disorder affects the quality of life and the working ability of the patients. It causes high risk of comorbidity and has a limited spontaneous recovery rate. Hitherto, no therapy guidelines are available and the patients actually may undergo no treatment. Therefore early therapy of subsyndromal anxiety disorder is recommended to avoid the onset into GAD. The herbal remedy Silexan, a novelty from lavender oil is recommended as a complementary therapy. This article offers an overview on the clinical studies of the efficacy and tolerability of the licensed phytopharmaceutic agent used in the treatment of restlessness during anxiety. *Gekürzte Fassung der englischsprachigen Erstpublikation: Kasper S et al. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder — evidence from clinical trials. Wien Med Wochenschr 2010; 160: 547–556
- 1 April 2011
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 32 (02) , 60-63
Wirksamkeit und Verträglichkeit von Silexan, einer neuen, oral verabreichten Zubereitung aus Lavendelöl, bei subsyndromaler Angststörung
Die subsyndromale Angststörung beeinflusst die Lebensqualität und die Arbeitsfähigkeit der Betroffenen und geht, ähnlich der generalisierten Angststörung (GAS), mit einem hohen Risiko der Komorbidität und mit einer geringen Spontanheilungsrate einher. Bisher gibt es keine Behandlungsrichtlinien und tatsächlich erfahren viele dieser Patienten keine Behandlung. Die frühzeitige Therapie der subsyndromalen Angst ist aber empfehlenswert, um einen Übergang in die GAS zu verhindern. Hierzu könnte Silexan, ein neues pflanzliches Arzneimittel aus Lavendelöl, beitragen. Dieser Artikel gibt einen Überblick über die klinischen Studien zur Wirksamkeit und Verträglichkeit dieses Phytopharmakons, welches zur Behandlung von Unruhezuständen bei ängstlicher Verstimmung zugelassen ist. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials On the same lines as the generalised anxiety disorder (GAD), a subthreshold also called subsyndromal anxiety disorder affects the quality of life and the working ability of the patients. It causes high risk of comorbidity and has a limited spontaneous recovery rate. Hitherto, no therapy guidelines are available and the patients actually may undergo no treatment. Therefore early therapy of subsyndromal anxiety disorder is recommended to avoid the onset into GAD. The herbal remedy Silexan, a novelty from lavender oil is recommended as a complementary therapy. This article offers an overview on the clinical studies of the efficacy and tolerability of the licensed phytopharmaceutic agent used in the treatment of restlessness during anxiety. *Gekürzte Fassung der englischsprachigen Erstpublikation: Kasper S et al. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder — evidence from clinical trials. Wien Med Wochenschr 2010; 160: 547–556
- Open Access
- 23 June 2006
- Published by Springer Nature in BMC Medicine
- Vol. 4 (1) , 14
Superior efficacy of St John's wort extract WS®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]
Background: The aim of the current study was to assess the antidepressant efficacy and safety of Hypericum perforatum (St. John's wort) extract WS® 5570 at doses of 600 mg/day in a single dose and 1200 mg/day in two doses. Methods: The participants in this double-blind, randomized, placebo-controlled, multi-center clinical trial were male and female adult out-patients with an episode of mild or moderate major depressive episode (single or recurrent episode, DSM-IV criteria). As specified by the relevant guideline, the study was preceded by a medication-free run-in phase. For the 6-week treatment, 332 patients were randomized: 123 to WS® 5570 600 mg/day, 127 to WS® 5570 1200 mg/day, and 82 to placebo. The primary outcome measure was the change in total score on the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and endpoint. Additional measures included the number of responders, the number of patients in remission, and several other standard rating scales. Efficacy and safety were assessed after 2 and 6 weeks. The design included an interim analysis performed after randomization with the option of early termination. Results: After 6 weeks of treatment, mean ± standard deviation decreases in HAM-D total scores of 11.6 ± 6.4, 10.8 ± 7.3, and 6.0 ± 8.1 points were observed for the WS® 5570 600 mg/day, 1200 mg/day and placebo groups, respectively (endpoint analysis). Secondary measures of treatment efficacy also showed that both WS® 5570 groups were statistically superior to placebo. Significantly more patients in the WS® 5570 treatment groups than in the placebo group showed treatment response and remission. WS® 5570 was consistently more effective than placebo in patients with either less severe or more severe baseline impairment. The number of patients who experienced remission was higher in the WS® 5570 1200 mg/day group than the WS® 5570 600 mg/day group. The incidence of adverse events was low in all groups. The adverse event profile was consistent with the known profile for Hypericum extract preparations. Conclusion: Hypericum perforatum extract WS® 5570 at doses of 600 mg/day (once daily) and 1200 mg/day (600 mg twice daily) were found to be safe and more effective than placebo, with comparable efficacy of the WS® 5570 groups for the treatment of mild to moderate major depression.
- 23 June 2006
- Published by Springer Nature in BMC Medicine
- Vol. 4 (1) , 14
Open AccessSuperior efficacy of St John's wort extract WS®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]
Background: The aim of the current study was to assess the antidepressant efficacy and safety of Hypericum perforatum (St. John's wort) extract WS® 5570 at doses of 600 mg/day in a single dose and 1200 mg/day in two doses. Methods: The participants in this double-blind, randomized, placebo-controlled, multi-center clinical trial were male and female adult out-patients with an episode of mild or moderate major depressive episode (single or recurrent episode, DSM-IV criteria). As specified by the relevant guideline, the study was preceded by a medication-free run-in phase. For the 6-week treatment, 332 patients were randomized: 123 to WS® 5570 600 mg/day, 127 to WS® 5570 1200 mg/day, and 82 to placebo. The primary outcome measure was the change in total score on the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and endpoint. Additional measures included the number of responders, the number of patients in remission, and several other standard rating scales. Efficacy and safety were assessed after 2 and 6 weeks. The design included an interim analysis performed after randomization with the option of early termination. Results: After 6 weeks of treatment, mean ± standard deviation decreases in HAM-D total scores of 11.6 ± 6.4, 10.8 ± 7.3, and 6.0 ± 8.1 points were observed for the WS® 5570 600 mg/day, 1200 mg/day and placebo groups, respectively (endpoint analysis). Secondary measures of treatment efficacy also showed that both WS® 5570 groups were statistically superior to placebo. Significantly more patients in the WS® 5570 treatment groups than in the placebo group showed treatment response and remission. WS® 5570 was consistently more effective than placebo in patients with either less severe or more severe baseline impairment. The number of patients who experienced remission was higher in the WS® 5570 1200 mg/day group than the WS® 5570 600 mg/day group. The incidence of adverse events was low in all groups. The adverse event profile was consistent with the known profile for Hypericum extract preparations. Conclusion: Hypericum perforatum extract WS® 5570 at doses of 600 mg/day (once daily) and 1200 mg/day (600 mg twice daily) were found to be safe and more effective than placebo, with comparable efficacy of the WS® 5570 groups for the treatment of mild to moderate major depression.
- 1 January 2005
- Published by S. Karger AG in Schweizerische Zeitschrift für Ganzheitsmedizin / Swiss Journal of Integrative Medicine
- Vol. 17 (6) , 336-337
Hypericumextrakt WS® 5570 versus Paroxetin. Ergebnisse einer kontrollierten, randomisierten Doppel-blindstudie bei Patienten mit mittelschweren bis schweren Depressionen
- 1 January 2005
- Published by S. Karger AG in Schweizerische Zeitschrift für Ganzheitsmedizin / Swiss Journal of Integrative Medicine
- Vol. 17 (6) , 336-337
Hypericumextrakt WS® 5570 versus Paroxetin. Ergebnisse einer kontrollierten, randomisierten Doppel-blindstudie bei Patienten mit mittelschweren bis schweren Depressionen
- 1 August 2002
- Published by Wiley in Wiener Medizinische Wochenschrift
- Vol. 152 (15-16) , 423-426
Ginkgoextrakt bei eingeschranktem Sehvermogen - Behandlung mit dem Spezialextrakt EGb 761R bei Beeintrachtigung aufgrund seniler trockener Makuladegeneration*
- 1 August 2002
- Published by Wiley in Wiener Medizinische Wochenschrift
- Vol. 152 (15-16) , 423-426
Ginkgoextrakt bei eingeschranktem Sehvermogen - Behandlung mit dem Spezialextrakt EGb 761R bei Beeintrachtigung aufgrund seniler trockener Makuladegeneration*